APRE - CIK 0001781983
The table below shows Aprea Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$2.76M | -$3.63M | -$3.94M | -$2.98M | -$5.50M | -$11.52M |
| Capital expenditure | - | - | $7.98K | - | - | - |
| Investing cash flow | - | - | -$7.98K | - | - | - |
| Dividends paid | - | - | - | - | - |
Aprea Therapeutics, Inc. reported operating cash flow of -$12.89M for fiscal year 2025. That is up 4.9% from -$13.56M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow grew from -$14.00M (FY 2017) to -$12.89M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $34.62M | $55.85K | $14.71M | $5.14M | - | - |